Lantern Pharma's LP-284 Gains FDA Orphan Drug Status for Soft Tissue Sarcomas
Event summary
- Lantern Pharma's LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas on January 20, 2026.
- This is the third orphan designation for LP-284, following previous designations for Mantle Cell Lymphoma and High-Grade B-Cell Lymphoma.
- Soft tissue sarcomas represent a global market of ~96,000 annual cases with limited treatment options.
- LP-284 targets DNA repair deficiencies via transcription-coupled nucleotide excision repair (TC-NER).
- The FDA's Orphan Drug Designation provides seven years of market exclusivity and other development incentives.
The big picture
Lantern Pharma's FDA Orphan Drug Designation for LP-284 in soft tissue sarcomas expands the drug's potential beyond hematologic malignancies into solid tumors. This strategic move aligns with the growing trend of AI-driven drug discovery, targeting rare cancers with significant unmet medical needs. The global soft tissue sarcoma market is projected to reach $4.7 billion by 2035, highlighting the commercial potential of successful therapies in this space.
What we're watching
- Clinical Progress
- How LP-284's synthetic lethal mechanism will perform in Phase 1 trials for soft tissue sarcomas.
- Market Potential
- Whether Lantern Pharma can leverage the orphan drug designation to accelerate LP-284's development and commercialization.
- AI-Driven Discovery
- The pace at which Lantern's RADR® AI platform can identify additional biomarker-driven opportunities in rare cancers.
Related topics